phrykt

Janux Therapeutics, Inc. (JANX): who owns it and who trades it

As of Nov 16, 2026, JANX insiders reported 10 open-market sales worth $457K and no purchases in the last 12 months, with 24% of the sale value made under pre-set 10b5-1 plans. The largest seller was Andrew Hollman Meyer (Chief Business Officer), with $136K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Janux Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns JANX

194 funds and institutions reported JANX shares worth $951M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 18.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Ra Capital Management, L.P.18.3%
BlackRock, Inc.10.1%
Prosight Management, LP6.2%
State Street Corp4.9%
FMR LLC (Fidelity)4.0%
Federated Hermes, Inc.3.9%
Point72 Asset Management, L.P.3.3%
Vanguard Capital Management LLC3.0%
TCG Crossover Management, LLC2.9%
Alyeska Investment Group, L.P.2.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.11.19M18.35%$172MNo change
BlackRock, Inc.6.13M10.06%$94.2M+13%
Prosight Management, LP3.80M6.24%$58.4M+7%
State Street Corp3.00M4.93%$46.2M+22%
FMR LLC (Fidelity)2.41M3.96%$37.1M-5%
Federated Hermes, Inc.2.35M3.86%$36.1M+4241%
Point72 Asset Management, L.P.1.99M3.27%$30.6M+72%
Vanguard Capital Management LLC1.86M3.05%$28.5M+3%
TCG Crossover Management, LLC1.79M2.93%$27.5MNo change
Alyeska Investment Group, L.P.1.65M2.70%$25.3M+3%
Nantahala Capital Management, LLC1.62M2.66%$24.9M+100%
Wellington Management Group LLP1.51M2.47%$23.2M-6%
Vanguard Portfolio Management LLC1.33M2.18%$20.4M+3%
Two Sigma Investments, LP1.21M1.98%$18.5M+940%
Geode Capital Management, LLC1.20M1.97%$18.5M+5%
Citadel Advisors LLC1.20M1.97%$18.4M+241%
Algert Global LLC1.11M1.82%$17.1M+151%
D. E. Shaw & Co., Inc.1.10M1.80%$16.8M+1014%
Goldman Sachs Group Inc952,6751.56%$14.6M+58%
Bank of America Corp910,4601.49%$14M+14%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, JANX insiders reported $0 of open-market purchases and $457K of sales. 24% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$457K
10 trades, 7 people
Sales under a 10b5-1 plan
24%
Share of sale value
Latest trade
Jun 2, 2026
Filed Jun 4, 2026

Purchases and sales by month

$261K$261KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 2, 2026Janeen Noel DoyleChief Corp. & Bus. Dev. Sale4,059$14.03$56.9KForm 4
May 11, 2026Maria DobekVice presidentSale2,038$14.17$28.9KForm 4
Jan 2, 2026Andrew Hollman MeyerChief Business OfficerSale1,879$13.73$25.8KForm 4
Jan 2, 2026Thomas DiRaimondoChief Scientific OfficerSale2,505$13.73$34.4KForm 4
Jan 2, 2026David Alan CampbellCEOSale8,072$13.73$111KForm 4
Jan 2, 2026Charles M. WinterChief Technical OfficerSale2,401$13.73$33KForm 4
Jan 2, 2026Zachariah McIverChief Medical OfficerSale2,714$13.73$37.3KForm 4
Jan 2, 2026Maria DobekVice presidentSale1,462$13.73$20.1KForm 4
Dec 1, 2025Andrew Hollman MeyerChief Business OfficerSale plan633$33.52$21.2KForm 4
Dec 1, 2025Andrew Hollman MeyerChief Business OfficerSale plan2,700$32.85$88.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Andrew Hollman MeyerChief Business Officer–$136KJan 2, 2026
David Alan CampbellPresident and CEO, Director–$111KJan 2, 2026
Janeen Noel DoyleChief Corp. & Bus. Dev. Ofcr–$56.9KJun 2, 2026
Maria DobekVice President, Accounting–$49KMay 11, 2026
Zachariah McIverChief Medical Officer–$37.3KJan 2, 2026
Thomas DiRaimondoChief Scientific Officer–$34.4KJan 2, 2026
Charles M. WinterChief Technical Officer–$33KJan 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

JANX short interest

Moderate short interest. 8.7% of JANX shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 32%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.33M JANX shares were sold short, 8.7% of the shares outstanding, up 0.1% from the report before. At the average daily volume of 667,598 shares, buying them all back would take about 8.0 trading days (days to cover).

Shares short, % of all shares

8.72%May 15Oct 3014.0%

Days to cover

8.0May 15Oct 3012.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.33M8.72%+0%667,5988.0
Oct 15, 20265.33M8.71%-6%859,8746.2
Sep 30, 20265.68M9.30%-4%969,5335.9
Sep 15, 20265.89M9.64%-3%999,8855.9
Aug 31, 20266.06M9.92%-8%776,4267.8
Aug 14, 20266.63M10.84%+12%607,94210.9
Jul 31, 20265.92M9.71%-8%765,2567.7
Jul 15, 20266.45M10.58%-9%1.00M6.4
Jun 30, 20267.11M11.66%-7%1.98M3.6
Jun 15, 20267.62M12.49%-6%694,79211.0
May 29, 20268.09M13.27%+3%1.18M6.8
May 15, 20267.83M12.83%-1%810,4619.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Janux Therapeutics company events

Janux Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jun 23, 2026AnnouncementWilliam Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Company’s Change in Control and Severance Benefit Plan (a copy of which is filed as Exhibit 10.12… Filing
  4. Jun 12, 2026VoteReported shareholder vote results. Filing
  5. May 7, 2026ResultsReleased financial results. Filing
  6. Apr 28, 2026LeadershipIn order to achieve a more equal balance of membership among the three classes of directors on the Board of Directors of Janux Therapeutics, Inc., the Board determined that one of its members should be reclassified from Class III (with a term expiring at the Company’s 2027 Annual Meeting of… Filing
  7. Feb 26, 2026ResultsReleased financial results. Filing
  8. Jan 22, 2026AgreementEntry into Material Definitive Agreement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Janux Therapeutics financials

Famous investors that hold JANX

4 of the 50 well-known investors we track reported holding JANX in their latest 13F filing. The largest position is Steve Cohen's, worth $27.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20261.58M$27.3M0.0%-21%
Ken Griffin · Citadel AdvisorsQ3 2026496,535$8.6M0.0%-59%
Israel Englander · Millennium ManagementQ3 2026219,110$3.8M0.0%-57%
Paul Tudor Jones · Tudor Investment CorpQ3 202623,307$403K0.0%-17%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named JANX in the last 120 days.

FiledHolderFormStake
Nov 13, 2026W. Lawrence Hawkins13G/A5.2%
Nov 13, 2026W. Lawrence Hawkins13G/A5.2%

Questions about Janux Therapeutics, Inc. (JANX) stock

Who owns the most JANX stock?

The largest reported owner of Janux Therapeutics, Inc. (JANX) is Ra Capital Management, L.P., with 18.3% of the company. In total, 194 funds and institutions reported holding JANX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are JANX insiders buying or selling?

In the last 12 months, JANX insiders reported no open-market purchases and 10 sales worth $457K. The latest trade was on Jun 2, 2026. See every trade.

What is the short interest in JANX?

As of Oct 30, 2026, 5.33M JANX shares were sold short, 8.7% of the shares outstanding, up 0.1% from the report before. At the average daily volume of 667,598 shares, buying them all back would take about 8.0 trading days (days to cover). See the history.

Which famous investors hold JANX?

4 of the 50 well-known investors we track reported JANX in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $27.3M. See all holders.

Executive pay

Janux Therapeutics's chief executive was paid a total of $13.5M for the year ended Dec 31, 2025, up 50% from $9M the year before. In the last 12 months, Janux Therapeutics's executives and directors bought no stock on the open market and sold $457K.

Chief executive, total pay$13.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$4.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.